Workflow
Bionexus Gene Lab (BGLC)
icon
Search documents
Bionexus Gene Lab (BGLC) - 2024 Q3 - Quarterly Report
2024-11-15 22:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ Commission File Number: 001-41750 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) | --- | --- | --- | |------------------ ...
BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.
GlobeNewswire News Room· 2024-09-25 15:31
KUALA LUMPUR, Malaysia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- MRNA Scientific Sdn. Bhd. ("MRNA"), a subsidiary of BioNexus Gene Lab Corp. (Nasdaq: BGLC, the "Company"), and Protech Builders Sdn. Bhd. ("Protech"), a leading mechanical and electrical engineering construction firm in Malaysia, are pleased to announce the signing of a strategic teaming agreement (the "Agreement") to jointly develop and operate biogas plants across Malaysia. This collaboration marks a significant step in both companies' efforts to ...
BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions
GlobeNewswire News Room· 2024-09-12 17:23
KUALA LUMPUR, Malaysia, Sept. 13, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC, the "Company"), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce the signing of a strategic partnership Memorandum of Understanding (MOU) with Shenzhen Rongguang Health Group, a major healthcare services provider in China. This partnership aims to expand the Company's expertise and presence in cancer screening, precision medicine, and preventative healthcare t ...
BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production
GlobeNewswire News Room· 2024-09-11 15:05
KUALA LUMPUR, Malaysia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp (Nasdaq: BGLC, the "Company"), an emerging Biotech & Chemicals company, is pleased to announce that its subsidiary, Chemrex Corporation Sdn. Bhd. (Chemrex), has invested approximately RM 2 million (approx. USD $450,000) to begin the production of fine-quality color paste (non-drying type) specifically designed for composite industrial customers. The new production facility will commence operations in late September 2024, marki ...
BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd
GlobeNewswire News Room· 2024-08-27 15:35
KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and personalized medicine, is pleased to announce the successful co-investment by the Securities Commission of Malaysia under its Malaysia CoInvestment Fund (MyCIF), into Ascension Innovation Sdn Bhd (AISB). This co-investment, alongside BGLC's recent investment, the first under its Environmental & Social Impact (ESI) Scheme shows confidence in the strategic direction a ...
BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd
GlobeNewswire News Room· 2024-08-26 16:15
KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and health technology, today announced the successful closing of its RM 1 million (Approx. USD228k) investment in Ascension Innovation Sdn Bhd (AISB), a pioneering Malaysian healthcare technology firm. This strategic investment, executed through BGLC's wholly-owned subsidiary, MRNA Scientific Sdn Bhd, solidifies BGLC's commitment to advancing AI-driven healthcare soluti ...
Bionexus Gene Lab (BGLC) - 2024 Q2 - Quarterly Report
2024-08-14 18:15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Wyoming 35-2604830 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) Title of each class Trading Symbol(s)Name of each exchange on which registered Common stock, no par value BGLC The Nasdaq Stock Market LLC Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated Filer ☒ Smaller reporting company ☒ Emerging growth company ☒ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) ...
Bionexus Gene Lab (BGLC) - 2024 Q1 - Quarterly Report
2024-05-15 17:20
Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective period and year: | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------|---------------------------------------|---------------------------------------| | | March 31, 2024 | December 31, 2023 | | Period ended March 31, 2024 /Year-ended December 31, 2023 US$1: MYR exchange rate | 4.7205 | 4.5900 | | | January 1, 2024 to March 3 ...
BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare
Newsfilter· 2024-04-18 18:52
KUALA LUMPUR, Malaysia, April 19, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corporation (NASDAQ:BGLC), a global leader in genomic diagnostics and healthcare technology, announces a strategic investment by its wholly owned subsidiary, MRNA Scientific Sdn Bhd, in Ascension Innovation Sdn Bhd (AISB), a privately held Malaysian company. This investment underscores BGLC's commitment to advancing healthcare solutions through cutting-edge AI and predictive analytics. Background: MRNA Scientific Sdn Bhd: A wholly- ...
Bionexus Gene Lab (BGLC) - 2023 Q4 - Annual Report
2024-04-16 17:00
39 Table of Contents Terms of Directors and Officers Our officers are elected by and serve at the discretion of the board of directors and the stockholders voting by ordinary resolution. Compensation of Directors and Executive Officers For the year ended December 31, 2023, we paid an aggregate of approximately $30,000 including 25,000 shares valued at $25,000, respectively, in cash and benefits to our executive officers. We do not have a share incentive program to provide for grants of awards to our directo ...